Abstract: Cancer stem cells (CSCs) drive tumor heterogeneity, therapeutic resistance, and cancer recurrence through various mechanisms of omics reprogramming. The WNT signaling pathway, encompassing both canonical and non-canonical cascades, plays a critical role in the survival, expansion, and metastasis of these CSCs. LGK974, also known as WNT974, has emerged as a promising targeted therapy for solid tumors and WNT-driven cancers. As a small-molecule porcupine (PORCN) inhibitor, LGK974 blocks the palmitoleoylation and subsequent secretion of WNT ligands, thereby starving tumors of essential WNT signals. Currently in Phase I and Phase I/II clinical trials for solid tumors and metastatic colorectal cancer, LGK974 demonstrates significant potential not only as a monotherapy but also in combination regimens with tyrosine kinase inhibitors (TKIs) and immune checkpoint blockers to overcome drug resistance and immune evasion.
1. Introduction
Cancer stem cells (CSCs) represent a subpopulation of cells within tumors that possess the capacity for self-renewal, differentiation, and de-differentiation. These cells undergo extensive epigenetic, epithelial-mesenchymal, immunological, and metabolic reprogramming to adapt to the tumor microenvironment, allowing them to survive therapeutic insults and host defenses [1]. The survival and clonal expansion of drug-resistant CSCs are primary drivers of early recurrence and late relapse in cancer patients [1].
Aberrant activation of the WNT signaling pathway is a major driver in various human malignancies, including breast, colorectal, lung, pancreatic, and prostate cancers, as well as leukemia and melanoma [1]. WNT signaling cascades cross-talk with other major pathways (such as FGF, Notch, and Hedgehog) to regulate the expression of functional CSC markers like CD44, CD133, and LGR5 [1]. To combat WNT-driven cancers, several targeted therapeutics have entered clinical development. Among these is LGK974 (WNT974), a small-molecule inhibitor targeting the WNT signaling cascade, which is currently being evaluated in clinical trials for the treatment of solid tumors [1].
2. Pharmacological Activity
LGK974 (WNT974) exhibits potent pharmacological activity by repressing the survival and tumor-initiating potential of CSCs. Preclinical studies have demonstrated its efficacy against various CSC populations, including lung cancer stem cells and chronic myeloid leukemia (CML) stem cells [1]. In the context of CML, LGK974 significantly reduced residual stem and progenitor cells following treatment with the BCR-ABL inhibitor nilotinib by blocking WNT ligand secretion into the bone marrow microenvironment [1].
Clinically, LGK974 has progressed into human trials for cancer patients. It is currently being evaluated in a Phase I clinical trial (NCT01351103) as a monotherapy for patients with solid tumors. Additionally, it is under investigation in a Phase I/II clinical trial (NCT02278133) as a combination therapy for metastatic colorectal cancer (mCRC) [1]. These studies highlight its broad applicability across different WNT-driven solid tumors and hematological malignancies.
3. Molecular Mechanism of Action
LGK974 functions as a targeted small-molecule inhibitor of porcupine (PORCN) [1]. PORCN is an essential membrane-bound O-acyltransferase located in the endoplasmic reticulum that catalyzes the palmitoleoylation of WNT family ligands. This lipid modification is a critical step required for the proper processing, secretion, and function of WNT proteins [1].
By inhibiting PORCN, LGK974 restrains the PORCN-dependent palmitoleoylation of WNT ligands. This action effectively obstructs WNT signaling by blocking the secretion of WNT ligands from the producing cells. Furthermore, the lack of palmitoleoylated WNT prevents the WNT-mediated oligomerization and activation of Frizzled (FZD) receptors on target cells [1]. Consequently, LGK974 shuts down both canonical (WNT/beta-catenin) and non-canonical WNT signaling cascades, depriving CSCs of the signals required for their maintenance, expansion, and survival [1].
4. Structure-Activity Relationship (SAR)
While the provided literature identifies LGK974 (WNT974) as a highly specific small-molecule PORCN inhibitor, detailed chemical structures and specific Structure-Activity Relationship (SAR) data for the compound are not discussed in the reviewed text [1]. The primary focus of its molecular design is its ability to selectively bind to and inhibit the enzymatic activity of PORCN in the endoplasmic reticulum, thereby preventing the lipid modification of WNT ligands [1].
5. Current Limitations
The clinical application of WNT signaling-targeted therapeutics like LGK974 faces several challenges. A major limitation is the complexity of WNT signaling cascades and the presence of genetic alterations in non-enzymatic signaling components, which has caused many WNT-targeted drugs to stall in preclinical or early clinical stages [1].
Furthermore, patient selection is critical for the success of PORCN inhibitors. Preclinical evidence indicates that PORCN inhibitors are applicable for the treatment of cancers driven by specific upstream mutations, such as RNF43, ZNRF3, RSPO2, or RSPO3 alterations. However, they are generally not effective for cancers driven by downstream mutations, such as APC or CTNNB1 (beta-catenin) mutations, because the signaling pathway in those tumors is constitutively activated downstream of the WNT-receptor level [1]. Additionally, the inherent plasticity of CSCs and their ability to undergo omics reprogramming can lead to acquired resistance, necessitating careful monitoring and combination strategies [1].
6. Future Perspectives
The future of LGK974 and other WNT-targeted therapies lies heavily in combination regimens and precision medicine. Because canonical WNT signals and oncogenic tyrosine kinases often converge to stabilize beta-catenin for CSC maintenance, combining LGK974 with tyrosine kinase inhibitors (TKIs)—such as BCR-ABL, EGFR, FLT3, KIT, or RET inhibitors—holds great promise for preventing CSC evasion and overcoming TKI resistance [1].
Moreover, WNT signaling plays a context-dependent role in tumor immunity and immune evasion. WNT pathway activation can lead to the accumulation of regulatory T cells and myeloid-derived suppressor cells, while depleting active T cells. Therefore, combining LGK974 with immune checkpoint blockers (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA4 antibodies) could yield synergistic anti-tumor effects by reversing immune tolerance in the tumor microenvironment [1].
To optimize these therapies, rigorous "omics monitoring" is mandatory. The integration of whole-genome sequencing, transcriptomic profiling, immunohistochemical tests, and patient-derived organoid screening before and during treatment will be essential to identify the appropriate patient subpopulations (e.g., those with RNF43/RSPO alterations) and to dynamically fine-tune LGK974-based therapies [1].
